FDA Adverse Event Injury Summary report: N

DOUBLE MOBILITY HC LINER 28/DMG

MDR report key: 6445970 · Received March 30, 2017

Report

Report Number
3005180920-2017-00143
Event Type
Injury
Date Received
March 30, 2017
Date of Event
March 1, 2017
Report Date
March 30, 2017
Manufacturer
MEDACTA INTERNATIONAL SA
Product Code
MEH
PMA / PMN Number
K092265
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
IL, US
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 1

ON 17 MARCH 2017 THE MEDICAL AFFAIRS DIRECTOR PERFORMED A CLINICAL EVALUATION AND COMMENTED AS FOLLOWS: ONE MONTH AFTER PRIMARY SURGERY, THE PATIENT WAS COMPLAINING ABOUT PAIN. ACCORDING TO THE REPORT, THE DOUBLE MOBILITY LINER WAS EXCHANGED DUE TO THE PRESENCE OF A HEMATOMA. THERE IS NO REASON TO SUSPECT THAT THE CAUSE MAY BE LINKED TO THE IMPLANTED DEVICES. BATCH REVIEW PERFORMED ON 27 MARCH 2017. LOT 160253: (B)(4) ITEMS MANUFACTURED AND RELEASED ON 29 APRIL 2016. EXPIRATION DATE: 2021-04-14. NO ANOMALIES FOUND RELATED TO THE PROBLEM. TO DATE, (B)(4) ITEMS OF THE SAME LOT HAVE BEEN ALREADY SOLD WITHOUT ANY SIMILAR REPORTED EVENT. ON 30 MARCH 2017 THE R&D PROJECT MANAGER PERFORMED A VISUAL INSPECTION AND COMMENTED AS FOLLOWS: THE PIECES WERE ANALYZED. SOME SIGNS WERE NOTICED ON THE SURFACE OF THE PE DM LINER AND SOME DARK SIGNS WERE NOTICED ON THE RIM OF THE CERAMIC BALL HEAD, PROBABLY OCCURRED DURING THE REVISION SURGERY. FROM THE RECEIVED PIECES IT IS NOT POSSIBLE TO DETERMINE THE ROOT CAUSE OF THE EVENT BUT THERE IS NO REASON TO SUSPECT A FAILURE OF THE DEVICE.

Description of Event or Problem · 1

THE PATIENT CAME IN COMPLAINING OF PAIN. THE SURGEON DETERMINED THE PATIENT HAD A HEMATOMA. THE SURGEON PERFORMED AN I & D AND SWAPPED HE POLY. THE SURGERY WAS COMPLETED SUCCESSFULLY. X-RAYS AND EXPLANTS ARE AVAILABLE.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
228132 DOUBLE MOBILITY HC LINER 28/DMG DOUBLE MOBILITY LINER MEH MEDACTA INTERNATIONAL SA 160253

Patients

Seq Age Sex Outcome Treatment
1 Required Intervention